Anirudha Lakshminarasimhan

Anirudha Lakshminarasimhan(crpfi)

Anirudha Lakshminarasimhan
Principal Scientist
anirudha.l@tigs.res.in

Education

  • PhD, Molecular Genetics Laboratory, School of Biosciences and Bioengineering, IIT Bombay, 2005
  • MSc Biotechnology, University of Madras, 1999

Experience

  • Senior Group Leader, Group Leader, Senior Scientist, Scientist, Associate Scientist at Aurigene Discovery Technologies Limited, a subsidiary of Dr. Reddy’s, 2006-2017
  • Postdoctoral fellow, Miller School of Medicine, University of Miami, Florida, 2005-2006

Expertise

  • Recombinant expression, purification, characterization, and crystallization of proteins
  • Rational and screen-based engineering of proteins- yeast genetics for selection and screening of mutants
  • Drug discovery – target identification, validation, hit identification, hit to lead, lead optimization

Areas of interest

Rare genetic disorders, infectious diseases

Publications

  • Pottayil G. Sasikumar, Naremaddepalli S. Sudarshan, Srinivas Adurthi, Raghuveer K. Ramachandra, Dodderi S. Samiulla, Anirudha Lakshminarasimhan et al. PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy. Commun Biol 4, 699 (2021). https://doi.org/10.1038/s42003-021-02191-1
  • Viswanath, V.K.; Gore, S.T.; Valiyaparambil, A.; Mukherjee, S.; Lakshminarasimhan, A. Plasmodium Chitinases: Revisiting a Target of Transmission-Blockade against Malaria. Protein Sci. 2021, 30, 1493–1501. https://doi.org/10.1002/pro.4095
  • Narasimha K Rao, Vijayashankar Nataraj, Mohan, Love Panchariya, Kirttija Palai, Sumalatha R Talapati, Anirudha Lakshminarasimhan, Murali Ramachandra, Thomas Antony. Ternary complex formation of AFN-1252 with Acinetobacter baumannii FabI and NADH: crystallographic and biochemical studies. Chem. Biol. Drug Des. (2020) https://doi.org/10.1111/cbdd.13686